{
  "run": {
    "id": "cmnr14fua04qnp658ewpukaxe",
    "region": "US",
    "assetId": "cmnr14f6904q4p658t1g3p5t9",
    "ticker": "KVUE",
    "snapshotId": "cmnr14fqj04qcp658bfauo3x8",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:21:17.360Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr14fqj04qcp658bfauo3x8",
      "assetId": "cmnr14f6904q4p658t1g3p5t9",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 17.34,
          "dayLow": 16.76,
          "volume": 16614675,
          "dayHigh": 17.34,
          "currency": "USD",
          "prevClose": 16.73,
          "week52Low": 14.02,
          "week52High": 25.17
        },
        "fundamentals": {
          "pe": 22.3246753246753,
          "beta": 0.311589871794855,
          "epsTTM": 0.77,
          "fcfTTM": 1277000000,
          "growth": {
            "epsYoy": 0.4259259259259259,
            "revenueYoy": -0.02141701714655451
          },
          "sector": "Perfumes, Cosmetics & Other Toilet Preparations",
          "margins": {
            "net": 0.09719650886008992,
            "gross": 0.581327691087014,
            "operating": 0.1596138587675218
          },
          "website": "http://kenvue.com",
          "industry": "Consumer products",
          "pegRatio": 0.524144551101073,
          "ebitdaTTM": 3052000000,
          "forwardPe": 15.7706422018349,
          "marketCap": 39600000000,
          "totalCash": 1382000000,
          "totalDebt": 8286000000,
          "debtEquity": 0.7390955311747391,
          "quickRatio": 0.6303594234628718,
          "revenueTTM": 15124000000,
          "companyName": "Kenvue Inc.",
          "priceToBook": 3.06114537854157,
          "currentRatio": 1.119868637110016,
          "dividendYield": 0.0479770875267766,
          "returnOnAssets": 0.05278086962766149,
          "returnOnEquity": 0.136553646075244,
          "analystOpinions": null,
          "businessSummary": "Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.",
          "enterpriseValue": null,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 22000,
          "sharesOutstanding": 1916732090,
          "enterpriseToEbitda": null,
          "analystTargetMedian": null,
          "enterpriseToRevenue": null,
          "operatingCashflowTTM": 2197000000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:21:17.227Z"
    },
    "results": [
      {
        "id": "cmnr14fue04qup658egbykfwk",
        "runId": "cmnr14fua04qnp658ewpukaxe",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"KVUE\",\"currency\":\"USD\",\"current_price\":17.34,\"target_price_6m\":18.50,\"target_price_12m\":19.40,\"recommendation\":\"BUY\",\"confidence\":0.60,\"thesis_bullets\":[\"Attractive 4.8% dividend yield provides downside support at current levels\",\"Forward PE ~15.8x undervalues stable consumer health franchise\",\"EPS grew 42.6% YoY driven by margin expansion and cost optimization\",\"Revenue decline of -2.1% YoY signals organic growth headwinds\",\"Stock trades 31% below 52-week high creating potential mean-reversion opportunity\"],\"key_drivers\":[{\"driver\":\"Margin expansion from post-separation cost optimization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Strong brand portfolio (Tylenol, Listerine, Neutrogena) supports pricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Dividend yield attracting income-oriented investors near lows\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Revenue headwinds from category softness and FX pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Elevated debt load ($8.3B) limits financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.31) offers defensive positioning in volatile markets\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Consumer trade-down risk to private label in health/beauty\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"FCF generation of ~$1.3B supports deleveraging and dividends\",\"impact\":\"HIGH\",\"direction\":\"POS\"}],\"risks\":[\"Continued organic revenue decline if consumer spending weakens further\",\"Debt servicing costs rise if refinancing occurs at higher rates\",\"Private label competition erodes brand premiums in key categories\",\"Foreign currency translation drags on international revenue\",\"Potential dividend pressure if FCF deteriorates meaningfully\",\"Regulatory changes in OTC health or personal care categories\"],\"assumptions\":{\"revenue_cagr_3y\":1.5,\"ebit_margin_target\":17.5,\"wacc\":8.0,\"terminal_multiple\":16.0},\"scenarios\":{\"bear\":{\"target_price\":15.00,\"prob\":0.20,\"notes\":\"Prolonged revenue declines and margin compression from competitive pressures.\"},\"base\":{\"target_price\":19.40,\"prob\":0.55,\"notes\":\"Modest revenue stabilization with margin expansion toward 17-18% EBIT.\"},\"bull\":{\"target_price\":23.00,\"prob\":0.25,\"notes\":\"Brand revitalization drives organic growth recovery with strong margin leverage.\"}},\"method_notes\":\"Blended valuation: forward PE (16-17x on ~$1.10 FY forward EPS) and FCF yield analysis (~3.2% current, compressing to ~6-7% normalized). EV/EBITDA ~15x on TTM supports base case. 12M expected return ~12% justifies BUY at moderate confidence given revenue uncertainty. Dividend yield provides floor. Weighted scenario price ~$19.4. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Continued organic revenue decline if consumer spending weakens further",
            "Debt servicing costs rise if refinancing occurs at higher rates",
            "Private label competition erodes brand premiums in key categories",
            "Foreign currency translation drags on international revenue",
            "Potential dividend pressure if FCF deteriorates meaningfully",
            "Regulatory changes in OTC health or personal care categories"
          ],
          "ticker": "KVUE",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Modest revenue stabilization with margin expansion toward 17-18% EBIT.",
              "target_price": 19.4
            },
            "bear": {
              "prob": 0.2,
              "notes": "Prolonged revenue declines and margin compression from competitive pressures.",
              "target_price": 15
            },
            "bull": {
              "prob": 0.25,
              "notes": "Brand revitalization drives organic growth recovery with strong margin leverage.",
              "target_price": 23
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 8,
            "revenue_cagr_3y": 1.5,
            "terminal_multiple": 16,
            "ebit_margin_target": 17.5
          },
          "key_drivers": [
            {
              "driver": "Margin expansion from post-separation cost optimization",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Strong brand portfolio (Tylenol, Listerine, Neutrogena) supports pricing",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Dividend yield attracting income-oriented investors near lows",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Revenue headwinds from category softness and FX pressure",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Elevated debt load ($8.3B) limits financial flexibility",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Low beta (0.31) offers defensive positioning in volatile markets",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Consumer trade-down risk to private label in health/beauty",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "FCF generation of ~$1.3B supports deleveraging and dividends",
              "impact": "HIGH",
              "direction": "POS"
            }
          ],
          "method_notes": "Blended valuation: forward PE (16-17x on ~$1.10 FY forward EPS) and FCF yield analysis (~3.2% current, compressing to ~6-7% normalized). EV/EBITDA ~15x on TTM supports base case. 12M expected return ~12% justifies BUY at moderate confidence given revenue uncertainty. Dividend yield provides floor. Weighted scenario price ~$19.4. Not investment advice.",
          "current_price": 17.34,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Attractive 4.8% dividend yield provides downside support at current levels",
            "Forward PE ~15.8x undervalues stable consumer health franchise",
            "EPS grew 42.6% YoY driven by margin expansion and cost optimization",
            "Revenue decline of -2.1% YoY signals organic growth headwinds",
            "Stock trades 31% below 52-week high creating potential mean-reversion opportunity"
          ],
          "target_price_6m": 18.5,
          "target_price_12m": 19.4
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 35118,
        "createdAt": "2026-04-09T05:21:17.360Z",
        "usage": {
          "inputTokens": 3647,
          "outputTokens": 1666,
          "costUsd": 0.059885
        }
      },
      {
        "id": "cmnr14fue04qxp6583u216iox",
        "runId": "cmnr14fua04qnp658ewpukaxe",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI_Equity_Research_v1\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"KVUE\",\n  \"currency\": \"USD\",\n  \"current_price\": 17.34,\n  \"target_price_6m\": 17.20,\n  \"target_price_12m\": 17.50,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\n    \"Strong brand equity in consumer health segments.\",\n    \"Post-spin-off cost efficiencies boosting margins.\",\n    \"Revenue stability with minor growth challenges.\",\n    \"Low beta provides defensive investment characteristics.\",\n    \"Dividend yield enhances total return potential.\"\n  ],\n  \"key_drivers\": [\n    { \"driver\": \"Brand portfolio strength\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Cost reduction initiatives\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Revenue growth headwinds\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"Debt management\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n    { \"driver\": \"Market competition\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n    { \"driver\": \"Product innovation\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Economic sensitivity\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n    { \"driver\": \"Regulatory environment\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n  ],\n  \"risks\": [\n    \"Persistent revenue decline.\",\n    \"Increased competitive pressures.\",\n    \"Spin-off integration issues.\",\n    \"Adverse regulatory changes.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.015,\n    \"ebit_margin_target\": 0.165,\n    \"wacc\": 0.075,\n    \"terminal_multiple\": 16\n  },\n  \"scenarios\": {\n    \"bear\": { \"target_price\": 16.00, \"prob\": 0.2, \"notes\": \"Revenue decline persists and margins contract.\" },\n    \"base\": { \"target_price\": 17.50, \"prob\": 0.6, \"notes\": \"Current trends continue with slight improvement.\" },\n    \"bull\": { \"target_price\": 19.00, \"prob\": 0.2, \"notes\": \"Successful innovation drives growth above expectations.\" }\n  },\n  \"method_notes\": \"Valuation based on DCF with assumed growth and margins. HOLD due to limited upside. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI_Equity_Research_v1",
          "risks": [
            "Persistent revenue decline.",
            "Increased competitive pressures.",
            "Spin-off integration issues.",
            "Adverse regulatory changes."
          ],
          "ticker": "KVUE",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Current trends continue with slight improvement.",
              "target_price": 17.5
            },
            "bear": {
              "prob": 0.2,
              "notes": "Revenue decline persists and margins contract.",
              "target_price": 16
            },
            "bull": {
              "prob": 0.2,
              "notes": "Successful innovation drives growth above expectations.",
              "target_price": 19
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.075,
            "revenue_cagr_3y": 0.015,
            "terminal_multiple": 16,
            "ebit_margin_target": 0.165
          },
          "key_drivers": [
            {
              "driver": "Brand portfolio strength",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Cost reduction initiatives",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Revenue growth headwinds",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Debt management",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Market competition",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Product innovation",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Economic sensitivity",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory environment",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on DCF with assumed growth and margins. HOLD due to limited upside. Not investment advice.",
          "current_price": 17.34,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Strong brand equity in consumer health segments.",
            "Post-spin-off cost efficiencies boosting margins.",
            "Revenue stability with minor growth challenges.",
            "Low beta provides defensive investment characteristics.",
            "Dividend yield enhances total return potential."
          ],
          "target_price_6m": 17.2,
          "target_price_12m": 17.5
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 346,
        "createdAt": "2026-04-09T05:21:17.360Z",
        "usage": {
          "inputTokens": 2141,
          "outputTokens": 4517,
          "costUsd": 0.002497
        }
      },
      {
        "id": "cmnr14fue04qvp658tlcfqulq",
        "runId": "cmnr14fua04qnp658ewpukaxe",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Analyst\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"KVUE\",\n  \"currency\": \"USD\",\n  \"current_price\": 17.34,\n  \"target_price_6m\": 18.50,\n  \"target_price_12m\": 19.50,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.7,\n  \"thesis_bullets\": [\n    \"Defensive consumer health portfolio offers stability amid macroeconomic uncertainty.\",\n    \"Attractive 4.8% dividend yield provides a strong floor for total return.\",\n    \"Forward P/E of 15.8x represents a discount to historical consumer staple peers.\",\n    \"Negative revenue growth (-2.1%) remains a key overhang requiring volume stabilization.\",\n    \"Margin expansion and cost-cutting post-J&J spinoff drive strong EPS growth.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Pricing Power\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Volume Declines\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Dividend Yield\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Debt Servicing Costs\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Brand Loyalty\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"FX Headwinds\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Cost Synergies\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    }\n  ],\n  \"risks\": [\n    \"Continued volume weakness if consumers trade down to private label alternatives.\",\n    \"Litigation risks inherited from J&J, despite indemnification agreements.\",\n    \"High debt load limits aggressive M&A or share buybacks in the near term.\",\n    \"Slower than expected top-line recovery in the Skin Health and Beauty segment.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.02,\n    \"ebit_margin_target\": 0.18,\n    \"wacc\": 0.075,\n    \"terminal_multiple\": 16.0\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 14.50,\n      \"prob\": 0.25,\n      \"notes\": \"Volumes continue to decline, margins compress, and multiple drops to 13x forward earnings.\"\n    },\n    \"base\": {\n      \"target_price\": 19.50,\n      \"prob\": 0.55,\n      \"notes\": \"Revenue stabilizes, margins improve slightly, and stock re-rates to 17.5x forward P/E.\"\n    },\n    \"bull\": {\n      \"target_price\": 23.00,\n      \"prob\": 0.2,\n      \"notes\": \"Strong volume recovery and successful premiumization drive multiple expansion to 20x.\"\n    }\n  },\n  \"method_notes\": \"Valuation based on a blend of 17.5x forward P/E and DCF (7.5% WACC, 2% terminal growth). The 12.5% upside plus 4.8% yield supports a BUY rating. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Analyst",
          "risks": [
            "Continued volume weakness if consumers trade down to private label alternatives.",
            "Litigation risks inherited from J&J, despite indemnification agreements.",
            "High debt load limits aggressive M&A or share buybacks in the near term.",
            "Slower than expected top-line recovery in the Skin Health and Beauty segment."
          ],
          "ticker": "KVUE",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Revenue stabilizes, margins improve slightly, and stock re-rates to 17.5x forward P/E.",
              "target_price": 19.5
            },
            "bear": {
              "prob": 0.25,
              "notes": "Volumes continue to decline, margins compress, and multiple drops to 13x forward earnings.",
              "target_price": 14.5
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong volume recovery and successful premiumization drive multiple expansion to 20x.",
              "target_price": 23
            }
          },
          "confidence": 0.7,
          "assumptions": {
            "wacc": 0.075,
            "revenue_cagr_3y": 0.02,
            "terminal_multiple": 16,
            "ebit_margin_target": 0.18
          },
          "key_drivers": [
            {
              "driver": "Pricing Power",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Volume Declines",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Dividend Yield",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Debt Servicing Costs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Brand Loyalty",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "FX Headwinds",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Cost Synergies",
              "impact": "MED",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on a blend of 17.5x forward P/E and DCF (7.5% WACC, 2% terminal growth). The 12.5% upside plus 4.8% yield supports a BUY rating. Not investment advice.",
          "current_price": 17.34,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Defensive consumer health portfolio offers stability amid macroeconomic uncertainty.",
            "Attractive 4.8% dividend yield provides a strong floor for total return.",
            "Forward P/E of 15.8x represents a discount to historical consumer staple peers.",
            "Negative revenue growth (-2.1%) remains a key overhang requiring volume stabilization.",
            "Margin expansion and cost-cutting post-J&J spinoff drive strong EPS growth."
          ],
          "target_price_6m": 18.5,
          "target_price_12m": 19.5
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "model": "gemini-3-pro-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 25367,
        "createdAt": "2026-04-09T05:21:17.360Z",
        "usage": {
          "inputTokens": 2471,
          "outputTokens": 874,
          "costUsd": 0.01543
        }
      },
      {
        "id": "cmnr14fue04qtp658d40noxe8",
        "runId": "cmnr14fua04qnp658ewpukaxe",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"KVUE\",\"currency\":\"USD\",\"current_price\":17.34,\"target_price_6m\":17.9,\"target_price_12m\":18.2,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Category-leading brands support resilient cash flow and pricing.\",\"Revenue has been soft, limiting multiple expansion.\",\"Margins have room to recover through mix and productivity.\",\"4.8% dividend yield cushions downside for defensive investors.\",\"Current valuation looks roughly fair given low growth and leverage.\"],\"key_drivers\":[{\"driver\":\"Brand pricing power\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Volume recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Productivity savings\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Emerging market growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FX translation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Litigation and remediation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Deleveraging\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Promotional intensity\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Slower volume recovery in key categories\",\"Product liability or OTC litigation costs\",\"FX headwinds reduce reported sales\",\"Debt load limits strategic flexibility\",\"Retailer promotions pressure margins\"],\"assumptions\":{\"revenue_cagr_3y\":2.5,\"ebit_margin_target\":17.5,\"wacc\":7.8,\"terminal_multiple\":14},\"scenarios\":{\"bear\":{\"target_price\":14.5,\"prob\":0.25,\"notes\":\"Sales stay flat and margin recovery stalls.\"},\"base\":{\"target_price\":18.2,\"prob\":0.5,\"notes\":\"Low-single-digit growth with modest margin improvement.\"},\"bull\":{\"target_price\":21.5,\"prob\":0.25,\"notes\":\"Innovation and savings drive faster earnings expansion.\"}},\"method_notes\":\"Base case uses snapshot fundamentals with a blended DCF/forward earnings cross-check, anchored on low-single-digit growth and modest margin recovery; no sell-side targets used. Snapshot quote fields remain authoritative. HOLD matches ~5% 12M upside and mixed evidence; not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "OpenAI o3",
          "risks": [
            "Slower volume recovery in key categories",
            "Product liability or OTC litigation costs",
            "FX headwinds reduce reported sales",
            "Debt load limits strategic flexibility",
            "Retailer promotions pressure margins"
          ],
          "ticker": "KVUE",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Low-single-digit growth with modest margin improvement.",
              "target_price": 18.2
            },
            "bear": {
              "prob": 0.25,
              "notes": "Sales stay flat and margin recovery stalls.",
              "target_price": 14.5
            },
            "bull": {
              "prob": 0.25,
              "notes": "Innovation and savings drive faster earnings expansion.",
              "target_price": 21.5
            }
          },
          "confidence": 0.63,
          "assumptions": {
            "wacc": 7.8,
            "revenue_cagr_3y": 2.5,
            "terminal_multiple": 14,
            "ebit_margin_target": 17.5
          },
          "key_drivers": [
            {
              "driver": "Brand pricing power",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Volume recovery",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Productivity savings",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Emerging market growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "FX translation",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Litigation and remediation",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Deleveraging",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Promotional intensity",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Base case uses snapshot fundamentals with a blended DCF/forward earnings cross-check, anchored on low-single-digit growth and modest margin recovery; no sell-side targets used. Snapshot quote fields remain authoritative. HOLD matches ~5% 12M upside and mixed evidence; not investment advice.",
          "current_price": 17.34,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Category-leading brands support resilient cash flow and pricing.",
            "Revenue has been soft, limiting multiple expansion.",
            "Margins have room to recover through mix and productivity.",
            "4.8% dividend yield cushions downside for defensive investors.",
            "Current valuation looks roughly fair given low growth and leverage."
          ],
          "target_price_6m": 17.9,
          "target_price_12m": 18.2
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0d4f4ec40f4a3acf0069d75ab4984c8197ba2f82c1682b1ada",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 44625,
        "createdAt": "2026-04-09T05:21:17.360Z",
        "usage": {
          "inputTokens": 2412,
          "outputTokens": 2116,
          "costUsd": 0.033845
        }
      },
      {
        "id": "cmnr14fue04qwp65879t5fbv1",
        "runId": "cmnr14fua04qnp658ewpukaxe",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Fundamental DCF and Peer Comps Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"KVUE\",\n  \"currency\": \"USD\",\n  \"current_price\": 17.34,\n  \"target_price_6m\": 18.5,\n  \"target_price_12m\": 19.8,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Iconic brands drive resilient consumer demand.\",\n    \"Forward PE 15.8x and 4.8% yield attractive.\",\n    \"EPS growth strong despite revenue softness.\",\n    \"Low beta provides defensive portfolio value.\",\n    \"Post-spin efficiencies to expand margins.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Brand portfolio strength\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Revenue growth recovery\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"EBIT margin expansion\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Consumer spending weakness\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Debt servicing costs\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Product innovation success\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Dividend yield support\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Regulatory OTC pressures\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Persistent revenue declines in key categories\",\n    \"Competition from generics and private label\",\n    \"Supply chain cost inflation\",\n    \"Product safety litigation exposure\",\n    \"Rising interest expense on debt\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 2.8,\n    \"ebit_margin_target\": 17.5,\n    \"wacc\": 7.2,\n    \"terminal_multiple\": 16.5\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 15.2,\n      \"prob\": 0.3,\n      \"notes\": \"Prolonged demand weakness triggers de-rating.\"\n    },\n    \"base\": {\n      \"target_price\": 19.8,\n      \"prob\": 0.45,\n      \"notes\": \"Stable brands and modest growth support upside.\"\n    },\n    \"bull\": {\n      \"target_price\": 24.0,\n      \"prob\": 0.25,\n      \"notes\": \"Innovation drives market share and acceleration.\"\n    }\n  },\n  \"method_notes\": \"DCF using revenue CAGR, EBIT target, WACC and terminal multiple; cross-checked with peers. 14% 12M upside drives BUY despite mixed revenue. not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Fundamental DCF and Peer Comps Model",
          "risks": [
            "Persistent revenue declines in key categories",
            "Competition from generics and private label",
            "Supply chain cost inflation",
            "Product safety litigation exposure",
            "Rising interest expense on debt"
          ],
          "ticker": "KVUE",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.45,
              "notes": "Stable brands and modest growth support upside.",
              "target_price": 19.8
            },
            "bear": {
              "prob": 0.3,
              "notes": "Prolonged demand weakness triggers de-rating.",
              "target_price": 15.2
            },
            "bull": {
              "prob": 0.25,
              "notes": "Innovation drives market share and acceleration.",
              "target_price": 24
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 7.2,
            "revenue_cagr_3y": 2.8,
            "terminal_multiple": 16.5,
            "ebit_margin_target": 17.5
          },
          "key_drivers": [
            {
              "driver": "Brand portfolio strength",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Revenue growth recovery",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "EBIT margin expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Consumer spending weakness",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Debt servicing costs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Product innovation success",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Dividend yield support",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Regulatory OTC pressures",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF using revenue CAGR, EBIT target, WACC and terminal multiple; cross-checked with peers. 14% 12M upside drives BUY despite mixed revenue. not investment advice.",
          "current_price": 17.34,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Iconic brands drive resilient consumer demand.",
            "Forward PE 15.8x and 4.8% yield attractive.",
            "EPS growth strong despite revenue softness.",
            "Low beta provides defensive portfolio value.",
            "Post-spin efficiencies to expand margins."
          ],
          "target_price_6m": 18.5,
          "target_price_12m": 19.8
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "e7ee47f0-2073-9799-ac20-8510b6535f5e",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 16245,
        "createdAt": "2026-04-09T05:21:17.360Z",
        "usage": {
          "inputTokens": 2746,
          "outputTokens": 3432,
          "costUsd": 0.059718
        }
      }
    ]
  }
}